Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

Sun Pharmaceuticals Industries Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 10:44 am

Market Cap 3,86,125 Cr.
Current Price 1,609
High / Low 1,960/1,377
Stock P/E32.8
Book Value 288
Dividend Yield0.84 %
ROCE17.3 %
ROE16.7 %
Face Value 1.00
PEG Ratio1.04

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Sun Pharmaceuticals Industries Ltd

Competitors of Sun Pharmaceuticals Industries Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
MPS Pharmaa Ltd 6.71 Cr. 3.51 4.33/3.05 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 53.1 Cr. 71.5 94.9/32.118.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 38.0 Cr. 26.0 29.0/8.7438.8 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 70.4 Cr. 93.5 155/79.011.4 55.40.00 %14.4 %15.5 % 10.0
Industry Average17,255.37 Cr1,081.8442.42185.800.37%16.00%16.32%6.27

All Competitor Stocks of Sun Pharmaceuticals Industries Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 9,8639,44710,76210,95211,24110,93111,94112,19212,38111,98312,65313,29113,675
Expenses 7,2577,1067,8777,9968,2378,1298,6099,0138,9048,9489,0459,3529,666
Operating Profit 2,6062,3402,8842,9573,0042,8023,3323,1793,4773,0353,6083,9394,009
OPM % 26%25%27%27%27%26%28%26%28%25%29%30%29%
Other Income 433-3,822285174202-118294180504533354149
Interest 19371419469381493574626952
Depreciation 554556588610660672651633622650655626631
Profit before tax 2,466-2,0762,2852,4122,4712,2402,4812,7913,0002,8163,4243,5983,476
Tax % 14%7%8%6%11%10%19%14%14%5%16%16%16%
Net Profit 2,126-2,2272,0932,2562,1811,9832,0062,3852,5612,6592,8613,0372,913
EPS in Rs 8.58-9.498.599.439.038.278.439.9010.5211.0611.8212.6712.10

Last Updated: February 28, 2025, 4:53 pm

Below is a detailed analysis of the quarterly data for Sun Pharmaceuticals Industries Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹13,675.00 Cr.. The value appears strong and on an upward trend. It has increased from 13,291.00 Cr. (Sep 2024) to ₹13,675.00 Cr., marking an increase of ₹384.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹9,666.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9,352.00 Cr. (Sep 2024) to ₹9,666.00 Cr., marking an increase of ₹314.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹4,009.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,939.00 Cr. (Sep 2024) to ₹4,009.00 Cr., marking an increase of ₹70.00 Cr..
  • For OPM %, as of Dec 2024, the value is 29.00%. The value appears to be declining and may need further review. It has decreased from 30.00% (Sep 2024) to 29.00%, marking a decrease of 1.00%.
  • For Other Income, as of Dec 2024, the value is ₹149.00 Cr.. The value appears to be declining and may need further review. It has decreased from 354.00 Cr. (Sep 2024) to ₹149.00 Cr., marking a decrease of 205.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹52.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 69.00 Cr. (Sep 2024) to ₹52.00 Cr., marking a decrease of 17.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹631.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 626.00 Cr. (Sep 2024) to ₹631.00 Cr., marking an increase of ₹5.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹3,476.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,598.00 Cr. (Sep 2024) to ₹3,476.00 Cr., marking a decrease of 122.00 Cr..
  • For Tax %, as of Dec 2024, the value is 16.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 16.00%.
  • For Net Profit, as of Dec 2024, the value is ₹2,913.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,037.00 Cr. (Sep 2024) to ₹2,913.00 Cr., marking a decrease of 124.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 12.10. The value appears to be declining and may need further review. It has decreased from ₹12.67 (Sep 2024) to 12.10, marking a decrease of ₹0.57.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 2:44 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 11,13116,08027,39228,48731,57826,48929,06632,83833,49838,65443,88648,49751,602
Expenses 6,3469,07819,49820,31321,47620,85822,68925,85525,02828,39732,23535,47937,012
Operating Profit 4,7847,0037,8948,17410,1025,6316,3776,9838,47010,25811,65013,01814,591
OPM % 43%44%29%29%32%21%22%21%25%27%27%27%28%
Other Income -90-1,968283-42610-135-258382-3,449-3,5054598651,540
Interest 4344579523400518555303141127172238256
Depreciation 3364091,1951,0381,2651,5001,7532,0532,0802,1442,5292,5572,562
Profit before tax 4,3154,5816,4036,5719,0483,4793,8105,0102,7994,4819,40811,08813,313
Tax % 20%15%14%14%13%26%16%16%18%24%9%13%
Net Profit 3,4693,8795,4765,6587,8462,5423,2084,1722,2723,3898,5139,61011,470
EPS in Rs 14.4015.1721.9218.8929.038.7311.1115.6912.1013.6435.3239.9147.65
Dividend Payout % 9%10%14%5%12%23%25%25%62%73%33%34%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)11.82%41.17%3.32%38.67%-67.60%26.20%30.05%-45.54%49.16%151.20%12.89%
Change in YoY Net Profit Growth (%)0.00%29.35%-37.85%35.35%-106.27%93.80%3.85%-75.59%94.71%102.03%-138.31%

Sun Pharmaceuticals Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: November 14, 2024, 7:34 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 104207207241240240240240240240240240240
Reserves 14,88618,31825,43132,74236,40038,07441,16945,02546,22347,77155,75563,42768,875
Borrowings 2602,5618,9968,4979,83210,38510,5148,3153,8691,2906,8863,2742,572
Other Liabilities 5,1288,00914,08913,94814,62415,59812,66614,61517,29120,47417,83118,36716,429
Total Liabilities 20,37729,09548,72355,42861,09564,29764,59068,19467,62269,77680,71285,30888,116
Fixed Assets 5,6476,81712,68215,87217,67518,85321,83722,84721,55322,66524,06523,21128,318
CWIP 5638422,0392,1752,8012,4651,4111,2201,5671,2874,9735,3541,150
Investments 2,4122,7862,7161,8301,1927,1437,90310,1439,61212,84914,82415,02617,744
Other Assets 11,75618,65031,28635,55039,42735,83733,43933,98434,89032,97536,84941,71740,904
Total Assets 20,37729,09548,72355,42861,09564,29764,59068,19467,62269,77680,71285,30888,116

Below is a detailed analysis of the balance sheet data for Sun Pharmaceuticals Industries Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹240.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹240.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹68,875.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹63,427.00 Cr. (Mar 2024) to ₹68,875.00 Cr., marking an increase of 5,448.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹2,572.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹3,274.00 Cr. (Mar 2024) to ₹2,572.00 Cr., marking a decrease of 702.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹16,429.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹18,367.00 Cr. (Mar 2024) to ₹16,429.00 Cr., marking a decrease of 1,938.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹88,116.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹85,308.00 Cr. (Mar 2024) to ₹88,116.00 Cr., marking an increase of 2,808.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹28,318.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹23,211.00 Cr. (Mar 2024) to ₹28,318.00 Cr., marking an increase of 5,107.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹1,150.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹5,354.00 Cr. (Mar 2024) to ₹1,150.00 Cr., marking a decrease of 4,204.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹17,744.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹15,026.00 Cr. (Mar 2024) to ₹17,744.00 Cr., marking an increase of 2,718.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹40,904.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹41,717.00 Cr. (Mar 2024) to ₹40,904.00 Cr., marking a decrease of 813.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹88,116.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹85,308.00 Cr. (Mar 2024) to ₹88,116.00 Cr., marking an increase of 2,808.00 Cr..

Notably, the Reserves (₹68,875.00 Cr.) exceed the Borrowings (2,572.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-256.005.00-1.000.001.00-5.00-4.00-2.005.009.005.0010.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days795068878310811210599999585
Inventory Days454410307370307338366311378315360338
Days Payable186174178207197234192142167158194194
Cash Conversion Cycle347286197251193212285274310255261229
Working Capital Days11112676104737913711284559378
ROCE %32%34%23%18%20%10%10%10%13%17%16%17%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%
FIIs14.44%14.95%16.00%16.87%16.88%16.48%16.78%17.08%17.72%17.23%18.01%18.04%
DIIs20.02%19.66%19.64%19.08%19.18%19.65%19.56%19.42%18.71%19.17%18.48%18.43%
Government0.00%0.00%0.06%0.06%0.06%0.09%0.10%0.11%0.11%0.11%0.11%0.11%
Public11.06%10.91%9.80%9.52%9.38%9.28%9.05%8.92%8.97%9.00%8.89%8.92%
No. of Shareholders6,62,3846,47,1676,43,5126,32,3376,25,2526,24,5616,16,5886,12,6266,31,3926,73,2176,57,3176,89,623

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
SBI Nifty 50 ETF19,868,4451.432502.3318,245,0022025-03-118.9%
ICICI Prudential Value Discovery Fund18,245,0026.122297.8718,245,0022025-03-110%
SBI S&P BSE Sensex ETF14,074,2371.651773.3518,245,0022025-03-11-22.86%
ICICI Prudential Equity & Debt Fund7,973,4963.371004.2218,245,0022025-03-11-56.3%
ICICI Prudential Bluechip Fund7,743,8812.03975.318,245,0022025-03-11-57.56%
Axis Bluechip Fund6,950,2902.64875.3518,245,0022025-03-11-61.91%
HDFC Balanced Advantage Fund - Regular Plan6,700,6121.15843.9118,245,0022025-03-11-63.27%
Nippon India Pharma Fund6,556,34912.76825.7418,245,0022025-03-11-64.06%
Aditya Birla Sun Life Flexi Cap Fund6,516,3594.24820.718,245,0022025-03-11-64.28%
HDFC Top 100 Fund - Regular Plan6,434,0092.68810.3318,245,0022025-03-11-64.74%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 39.9035.3013.6012.1015.70
Diluted EPS (Rs.) 39.9035.3013.6012.1015.70
Cash EPS (Rs.) 50.8746.2223.1318.1926.01
Book Value[Excl.RevalReserv]/Share (Rs.) 279.69247.22212.84206.23204.75
Book Value[Incl.RevalReserv]/Share (Rs.) 279.69247.22212.84206.23204.75
Revenue From Operations / Share (Rs.) 202.13182.91161.11139.62136.86
PBDIT / Share (Rs.) 59.9251.1947.1838.8731.78
PBIT / Share (Rs.) 49.2740.6438.2430.2023.23
PBT / Share (Rs.) 46.2139.2118.6811.6720.88
Net Profit / Share (Rs.) 40.2135.6814.209.5217.45
NP After MI And SOA / Share (Rs.) 39.9135.3213.6412.1015.69
PBDIT Margin (%) 29.6427.9829.2827.8423.22
PBIT Margin (%) 24.3722.2223.7321.6316.97
PBT Margin (%) 22.8621.4311.598.3515.25
Net Profit Margin (%) 19.8919.508.816.8212.75
NP After MI And SOA Margin (%) 19.7419.308.468.6611.46
Return on Networth / Equity (%) 15.0415.136.816.248.31
Return on Capital Employeed (%) 17.2616.0217.4414.0610.60
Return On Assets (%) 11.2010.494.684.295.51
Long Term Debt / Equity (X) 0.000.000.000.010.04
Total Debt / Equity (X) 0.040.110.010.070.16
Asset Turnover Ratio (%) 0.580.580.560.490.49
Current Ratio (X) 2.562.002.041.892.02
Quick Ratio (X) 1.981.481.511.331.51
Inventory Turnover Ratio (X) 0.670.790.780.720.69
Dividend Payout Ratio (NP) (%) 30.2629.7365.9653.6836.62
Dividend Payout Ratio (CP) (%) 23.8822.8939.8531.2823.70
Earning Retention Ratio (%) 69.7470.2734.0446.3263.38
Cash Earning Retention Ratio (%) 76.1277.1160.1568.7276.30
Interest Coverage Ratio (X) 60.2971.4088.8865.9525.19
Interest Coverage Ratio (Post Tax) (X) 43.5351.7763.6047.6015.69
Enterprise Value (Cr.) 384570.80239622.86218440.19143296.7489454.34
EV / Net Operating Revenue (X) 7.935.465.654.282.72
EV / EBITDA (X) 26.7519.5119.3015.3611.73
MarketCap / Net Operating Revenue (X) 8.025.375.684.282.57
Retention Ratios (%) 69.7370.2634.0346.3163.37
Price / BV (X) 6.114.214.573.091.87
Price / Net Operating Revenue (X) 8.025.375.684.282.57
EarningsYield 0.020.030.010.020.04

After reviewing the key financial ratios for Sun Pharmaceuticals Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 39.90. This value is within the healthy range. It has increased from 35.30 (Mar 23) to 39.90, marking an increase of 4.60.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 39.90. This value is within the healthy range. It has increased from 35.30 (Mar 23) to 39.90, marking an increase of 4.60.
  • For Cash EPS (Rs.), as of Mar 24, the value is 50.87. This value is within the healthy range. It has increased from 46.22 (Mar 23) to 50.87, marking an increase of 4.65.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 279.69. It has increased from 247.22 (Mar 23) to 279.69, marking an increase of 32.47.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 279.69. It has increased from 247.22 (Mar 23) to 279.69, marking an increase of 32.47.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 202.13. It has increased from 182.91 (Mar 23) to 202.13, marking an increase of 19.22.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 59.92. This value is within the healthy range. It has increased from 51.19 (Mar 23) to 59.92, marking an increase of 8.73.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 49.27. This value is within the healthy range. It has increased from 40.64 (Mar 23) to 49.27, marking an increase of 8.63.
  • For PBT / Share (Rs.), as of Mar 24, the value is 46.21. This value is within the healthy range. It has increased from 39.21 (Mar 23) to 46.21, marking an increase of 7.00.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 40.21. This value is within the healthy range. It has increased from 35.68 (Mar 23) to 40.21, marking an increase of 4.53.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 39.91. This value is within the healthy range. It has increased from 35.32 (Mar 23) to 39.91, marking an increase of 4.59.
  • For PBDIT Margin (%), as of Mar 24, the value is 29.64. This value is within the healthy range. It has increased from 27.98 (Mar 23) to 29.64, marking an increase of 1.66.
  • For PBIT Margin (%), as of Mar 24, the value is 24.37. This value exceeds the healthy maximum of 20. It has increased from 22.22 (Mar 23) to 24.37, marking an increase of 2.15.
  • For PBT Margin (%), as of Mar 24, the value is 22.86. This value is within the healthy range. It has increased from 21.43 (Mar 23) to 22.86, marking an increase of 1.43.
  • For Net Profit Margin (%), as of Mar 24, the value is 19.89. This value exceeds the healthy maximum of 10. It has increased from 19.50 (Mar 23) to 19.89, marking an increase of 0.39.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 19.74. This value is within the healthy range. It has increased from 19.30 (Mar 23) to 19.74, marking an increase of 0.44.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 15.04. This value is within the healthy range. It has decreased from 15.13 (Mar 23) to 15.04, marking a decrease of 0.09.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 17.26. This value is within the healthy range. It has increased from 16.02 (Mar 23) to 17.26, marking an increase of 1.24.
  • For Return On Assets (%), as of Mar 24, the value is 11.20. This value is within the healthy range. It has increased from 10.49 (Mar 23) to 11.20, marking an increase of 0.71.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 23) which recorded 0.00.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.04. This value is within the healthy range. It has decreased from 0.11 (Mar 23) to 0.04, marking a decrease of 0.07.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.58. There is no change compared to the previous period (Mar 23) which recorded 0.58.
  • For Current Ratio (X), as of Mar 24, the value is 2.56. This value is within the healthy range. It has increased from 2.00 (Mar 23) to 2.56, marking an increase of 0.56.
  • For Quick Ratio (X), as of Mar 24, the value is 1.98. This value is within the healthy range. It has increased from 1.48 (Mar 23) to 1.98, marking an increase of 0.50.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.67. This value is below the healthy minimum of 4. It has decreased from 0.79 (Mar 23) to 0.67, marking a decrease of 0.12.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 30.26. This value is within the healthy range. It has increased from 29.73 (Mar 23) to 30.26, marking an increase of 0.53.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 23.88. This value is within the healthy range. It has increased from 22.89 (Mar 23) to 23.88, marking an increase of 0.99.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 69.74. This value is within the healthy range. It has decreased from 70.27 (Mar 23) to 69.74, marking a decrease of 0.53.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 76.12. This value exceeds the healthy maximum of 70. It has decreased from 77.11 (Mar 23) to 76.12, marking a decrease of 0.99.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 60.29. This value is within the healthy range. It has decreased from 71.40 (Mar 23) to 60.29, marking a decrease of 11.11.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 43.53. This value is within the healthy range. It has decreased from 51.77 (Mar 23) to 43.53, marking a decrease of 8.24.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 384,570.80. It has increased from 239,622.86 (Mar 23) to 384,570.80, marking an increase of 144,947.94.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 7.93. This value exceeds the healthy maximum of 3. It has increased from 5.46 (Mar 23) to 7.93, marking an increase of 2.47.
  • For EV / EBITDA (X), as of Mar 24, the value is 26.75. This value exceeds the healthy maximum of 15. It has increased from 19.51 (Mar 23) to 26.75, marking an increase of 7.24.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 8.02. This value exceeds the healthy maximum of 3. It has increased from 5.37 (Mar 23) to 8.02, marking an increase of 2.65.
  • For Retention Ratios (%), as of Mar 24, the value is 69.73. This value is within the healthy range. It has decreased from 70.26 (Mar 23) to 69.73, marking a decrease of 0.53.
  • For Price / BV (X), as of Mar 24, the value is 6.11. This value exceeds the healthy maximum of 3. It has increased from 4.21 (Mar 23) to 6.11, marking an increase of 1.90.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 8.02. This value exceeds the healthy maximum of 3. It has increased from 5.37 (Mar 23) to 8.02, marking an increase of 2.65.
  • For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 23) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Sun Pharmaceuticals Industries Ltd as of March 12, 2025 is: ₹1,272.64

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Sun Pharmaceuticals Industries Ltd is Overvalued by 20.90% compared to the current share price 1,609.00

Intrinsic Value of Sun Pharmaceuticals Industries Ltd as of March 12, 2025 is: 1,674.02

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Sun Pharmaceuticals Industries Ltd is Undervalued by 4.04% compared to the current share price 1,609.00

Last 5 Year EPS CAGR: 31.54%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 18.33%, which is a positive sign.
  2. The company has higher reserves (41,084.31 cr) compared to borrowings (5,942.38 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (31.77 cr) and profit (6.08 cr) over the years.
  1. The stock has a high average Working Capital Days of 94.00, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 258.33, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sun Pharmaceuticals Industries Ltd:
    1. Net Profit Margin: 19.89%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 17.26% (Industry Average ROCE: 16%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 15.04% (Industry Average ROE: 16.32%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 43.53
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.98
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 32.8 (Industry average Stock P/E: 42.42)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.04
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Sun Pharmaceutical Industries Ltd. is a Public Limited Listed company incorporated on 01/03/1993 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1993PLC019050 and registration number is 019050. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 20275.17 Cr. and Equity Capital is Rs. 239.93 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
PharmaceuticalsSun Pharma Advanced Research Centre (SPARC), Tandalja, Vadodra Gujarat 390012secretarial@sunpharma.com
http://www.sunpharma.com
Management
NamePosition Held
Mr. Dilip S ShanghviChairman & Managing Director
Mr. Aalok D ShanghviWhole Time Director
Mr. Sudhir V ValiaNon Exe.Non Ind.Director
Dr. Pawan GoenkaLead Independent Director
Mr. Rama BijapurkarIndependent Director
Mr. Gautam DoshiIndependent Director
Mr. Sanjay AsherIndependent Director
Mr. Rolf HoffmannIndependent Director

FAQ

What is the latest intrinsic value of Sun Pharmaceuticals Industries Ltd?

The latest intrinsic value of Sun Pharmaceuticals Industries Ltd as on 08 March 2025 is ₹1272.64, which is 20.90% lower than the current market price of 1,609.00, indicating the stock is overvalued by 20.90%. The intrinsic value of Sun Pharmaceuticals Industries Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹3,86,125 Cr. and recorded a high/low of ₹1,960/1,377 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹68,875 Cr and total liabilities of ₹88,116 Cr.

What is the Market Cap of Sun Pharmaceuticals Industries Ltd?

The Market Cap of Sun Pharmaceuticals Industries Ltd is 3,86,125 Cr..

What is the current Stock Price of Sun Pharmaceuticals Industries Ltd as on 08 March 2025?

The current stock price of Sun Pharmaceuticals Industries Ltd as on 08 March 2025 is ₹1,609.

What is the High / Low of Sun Pharmaceuticals Industries Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Sun Pharmaceuticals Industries Ltd stocks is ₹1,960/1,377.

What is the Stock P/E of Sun Pharmaceuticals Industries Ltd?

The Stock P/E of Sun Pharmaceuticals Industries Ltd is 32.8.

What is the Book Value of Sun Pharmaceuticals Industries Ltd?

The Book Value of Sun Pharmaceuticals Industries Ltd is 288.

What is the Dividend Yield of Sun Pharmaceuticals Industries Ltd?

The Dividend Yield of Sun Pharmaceuticals Industries Ltd is 0.84 %.

What is the ROCE of Sun Pharmaceuticals Industries Ltd?

The ROCE of Sun Pharmaceuticals Industries Ltd is 17.3 %.

What is the ROE of Sun Pharmaceuticals Industries Ltd?

The ROE of Sun Pharmaceuticals Industries Ltd is 16.7 %.

What is the Face Value of Sun Pharmaceuticals Industries Ltd?

The Face Value of Sun Pharmaceuticals Industries Ltd is 1.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Sun Pharmaceuticals Industries Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE